Jon Napitupulu

Incyte announced positive Phase 3 inMIND trial results for tafasitamab combined with lenalidomide and rituximab in relapsed or refractory...

The Phase 3 inMIND trial showed positive results for tafasitamab combined with lenalidomide and rituximab in treating relapsed or...

Acticor Biotech, a clinical-stage biopharmaceutical company developing glenzocimab for cardiovascular emergencies, faces liquidation as the court-appointed administrator has requested...

BeiGene, soon to be BeOne Medicines, presented positive clinical data for BRUKINSA (zanubrutinib) and other pipeline assets in chronic...

Bristol Myers Squibb (BMS) presented 18 analyses at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the...

A five-year follow-up analysis of the ZUMA-5 Phase 2 study shows promising results for Yescarta (axicabtagene ciloleucel) in patients...

Kite, a Gilead Company, presented promising data on Tecartus (brexucabtagene autoleucel) for relapsed/refractory mantle cell lymphoma (R/R MCL) and...

The DREAMM-7 trial interim analysis revealed that belantamab mafodotin combined with bortezomib and dexamethasone (BVd) significantly improved overall survival...

Star Therapeutics announced interim Phase 1 clinical trial data for VGA039, a novel subcutaneous monoclonal antibody for Von Willebrand...

Stoke Therapeutics announced positive data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen, a drug candidate for...